AACR 2022: AACR taskforce tackles trust in science

Apr 10, 2022
2022 04 11 19 28 3667 Nodora Thumbnail 400

NEW ORLEANS -- On day four of the American Association for Cancer Research (AACR) meeting, LabPulse.com spoke with Dr. Jesse Nodora, PhD, of the Moores Cancer Center at the University of California San Diego Health, a member of the new AACR taskforce devoted to the concept of trust in science.

In our video interview, Nodora explains the motivation for establishing a new task force on trust in science, the challenges of community engagement, and how public trust in science has shifted during the COVID-19 pandemic, among other topics.

Watch the video below to learn more.


Latest in 2022
2022 05 03 19 56 4723 2022 05 03 Elhadi Aacr 400
How has the COVID-19 pandemic affected pediatric care?
May 2, 2022
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
2022 04 29 20 08 5415 2022 04 29 Aacr Tandler Walz 400
CoVac-1 vaccine shows promise for immunocompromised patients
May 1, 2022
2022 04 13 20 41 6411 Kader Thumbnail 400
AACR 2022 video: DCIS lesions may affect treatment
April 12, 2022
Related Stories
2022 05 03 19 56 4723 2022 05 03 Elhadi Aacr 400
Pediatric Cancer
How has the COVID-19 pandemic affected pediatric care?
2022 05 03 13 14 8568 2022 05 02 Aacr Parwani 400
Pathology, histology
New task force promotes pathology for cancer research
2022 04 29 20 08 5415 2022 04 29 Aacr Tandler Walz 400
Immunocompromised
CoVac-1 vaccine shows promise for immunocompromised patients
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in 2022
How has the COVID-19 pandemic affected pediatric care?
Elhadi, an assistant professor of health, behavior, and policy at the university discussed his research on the impact of the COVID-19 pandemic on pediatric cancer patients with LabPulse.com at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
2022 05 03 19 56 4723 2022 05 03 Elhadi Aacr 400
New task force promotes pathology for cancer research
By LabPulse.com staff writers
Efforts of the task force include an award program for outstanding pathology research in cancer, knowledge hubs on pathology for medical students, and the development and adoption of new technologies in pathology. Parwani shed light on the new task force in an interview with LabPulse at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
2022 05 03 13 14 8568 2022 05 02 Aacr Parwani 400
CoVac-1 vaccine shows promise for immunocompromised patients
Walz's team used their expertise with cancer therapeutics to develop a vaccine that induces T cells in immunocompromised patients who do not produce an adequate immune response to other vaccines.
May 1, 2022
2022 04 29 20 08 5415 2022 04 29 Aacr Tandler Walz 400
AACR 2022 video: DCIS lesions may affect treatment
In the study, Kader et al found that patients with recurrent DCIS lesions that are genetically distinct from the primary tumor may require different treatment.
April 12, 2022
2022 04 13 20 41 6411 Kader Thumbnail 400
Guardant highlights data on multicancer test at AACR 2022
By LabPulse.com staff writers
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
2017 09 14 23 05 1167 Cancer Cell 400
AACR 2022: Project GENIE spurs sharing of real-world data
GENIE, which stands for Genomics Evidence Neoplasia Information Exchange, is a publicly accessible international cancer registry of real-world data assembled by the AACR through data sharing between 19 of the leading cancer centers in the world.
April 11, 2022
2022 04 12 20 37 1672 Sweeney Thumbnail 400
Natera highlights Signatera data at AACR
By LabPulse.com staff writers
One study focuses on circulating tumor DNA (ctDNA) prognosis in adjuvant triple-negative breast cancer. Researchers found that 19.9% of patients with early-stage disease were found to have detectable ctDNA after surgery (which was strongly associated with poorer outcomes), and that lead time between first ctDNA positivity and recurrence on imaging was a median of six months.
April 10, 2022
2019 04 15 22 17 2307 Breast Cancer 400
Accounting for genetic factors may improve PSA testing
By LabPulse.com staff writers
Presenter Linda Kachuri, PhD, of the University of California, San Francisco, and colleagues investigated whether particular genetic factors could cause variations in PSA levels that are not due to cancer, and whether accounting for these could improve PSA testing. They conducted a study that included 95,000 men with diagnosed prostate cancer from cohorts in the U.S., the U.K., and Sweden and identified 128 PSA-associated variants they used to "build a polygenic score for PSA levels."
April 10, 2022
2019 10 16 20 31 7121 Cancer Cells Prostate 400
AACR 2022: Video preview of day 3
Even though Sunday is day three of the conference, it is the official launch day of the AACR's annual meeting. LabPulse.com will follow the AACR's presidential address given by AACR President David Tuveson and will talk to Shawn Sweeney, the director of Project GENIE (Genomics Evidence Neoplasia Information Exchange). Watch the video below for more.
April 9, 2022
2022 04 09 20 27 4107 Aacr Sign Square
AACR 2022: What's the microbiome's role in cancer risk?
By Leah Sherwood
Tossas, an assistant professor in the department of health behavior and policy at Virginia Commonwealth University, was acknowledged by the AACR as a Next-Gen Star, the organization's program that supports early-career scientists.
April 9, 2022
2022 04 10 15 36 4856 2022 04 10 Tossas Katherine Aacr 400
AACR 2022 video: Pathomics for cancer research
Knudsen addressed the topic of pathomics in cancer research and what that means for the field of pathology.
April 8, 2022
2022 04 10 00 41 7192 2022 04 09 Knudsen 400
Video from AACR 2022: Next-gen pathology tools for cancer research
Knudsen addressed the topic of pathomics in cancer research and what that means for the field of pathology.
April 8, 2022
2022 04 10 00 08 8403 2022 04 09 Knudsen 400
Page 1 of 2
Next Page